Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy Academic Article uri icon

Overview

MeSH Major

  • Amylases
  • Antineoplastic Combined Chemotherapy Protocols
  • Lipase
  • Melanoma
  • Pancreatitis

abstract

  • The majority of patients receiving BRAF-MEK inhibition after PD-1 therapy require dose interruptions, and a significant minority require hospitalization for AEs. In this higher risk population, the median time receiving therapy and OS may be inferior to those presented in published phase 3 trials.

publication date

  • March 15, 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.31889

PubMed ID

  • 30521084

Additional Document Info

start page

  • 884

end page

  • 891

volume

  • 125

number

  • 6